Activated c-Abl tyrosine kinase in malignant solid tumors

Oncogene

Volumn 27, Issue 32, 2008, Pages 4385-4391

  Lin, J ^a   Arlinghaus, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; c Abl; FUS1; Imatinib; Lung cancer; NSCLC

Indexed keywords

ABELSON KINASE; IMATINIB;

APOPTOSIS; BREAST CANCER; CANCER INVASION; CANCER STAGING; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; DRUG MECHANISM; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 47949106116     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.86     Document Type: Review

References (36)

1. Buchdunger E, Zimmerman J, Mett H, Meyer T, Muller M, Druker B et al. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104.
2. Bunn P, Franklin W. (2002). Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 29(5 Suppl 14): 38-44.
3. Dowell J, Minna J. (2005). Chasing mutations in the epidermal growth factor in lung cancer. N Engl J Med 352: 830-832.
4. Girard L, Zochbauer-Muller S, Virmani A, Gazdar A, Minna J. (2000). Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60: 4894-4906.
5. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuryian J et al. (2003). A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112: 845-857.
6. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch C et al. (2004). Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11: 1-7.
7. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C et al. (2002). Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62: 2715-2720.
8. Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y et al. (2001). Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 20: 6258-6262.
9. LeRoith D, Werner H, Beitner-Johnson D, Roberts C. (1995). Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163.
10. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J et al. (2007). Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26: 6989-6996.
11. Lin J, Sun T, Lin J, Minna J, Roth J, Arlinghaus R. (2005). Activated c-Abl in FUS1 haploinsufficient non-small cell lung carcinoma. 96th Annual American Association for Cancer Research (Abstract 2877).
12. Ling X, Ma G, Sun T, Liu J, Arlinghaus R. (2003). Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. Cancer Res 63: 298-303.
13. Liu J, Wu Y, Arlinghaus R. (1996). Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56: 5120-5124.
14. Ma Z, Dong A, Kong M, Qian J. (2007). Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apotosis and inhibits invasion in human lung adenocarcinoma A549 cells. Cell Mol Biol Lett 12: 556-572.
15. Miller C, Chen G, Gharib T, Wang H, Thomas D, Misek D et al. (2003). Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22: 7950-7957.
16. Negri T, Casieri P, Miselli F, Orsenigo M, Piacenza C, Stacchiotti S et al. (2007). Evidence for PDGFR-α, PDGFR-β and KIT deregulation in an NSCLC patient. Br J Cancer 96: 180-181.
17. Osherov N, Levitzki A. (1994). Epidermal-growth-factor-dependent activation of the Src-family kinases. Eur J Biochem 225: 1047-1053.
18. Pendergast A. (2002). The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85: 51-100.
19. Plattner R, Kadlec L, DeMali K, Kazlauskas A, Pendergast A. (1999). c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13: 2400-2411.
20. Plattner R, Pendergast AM. (2003). Activation and signaling of the Abl tyrosine kinase: bidirectional link with phosphoinositide signaling. Cell Cycle 2: 273-274.
21. Pluk H, Dorey K, Superti-Furga G. (2002). Autoinhibition of c-Abl. Cell 108: 247-259.
22. Prudkin L, Behrens C, Liu D, Zhou X, Ozburn N, Bekele B et al. (2008). Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Hum Cancer Biol 14: 41-47.
23. Ross S, Fletcher A. (1998). The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428.
24. Sirvent A, Boureux A, Simon V, Leroy C, Roche S. (2007). The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cell lines. Oncogene 26: 7313-7323.
25. Srinivasan D, Plattner R. (2006). Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66: 5648-5655.
26. Srinivasan D, Sims J, Plattner R. (2008). Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27: 1095-1105.
27. Taagepera S, McDonald D, Loeb J, Whitaker L, McElroy A, Wang J et al. (1998). Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA 95: 7457-7462.
28. Tanos B, Pendergast AM. (2006). Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 28: 32714-32723.
29. Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson E et al. (2004). Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 64: 2969-2976.
30. U.S. Cancer Statistics Working Group (2004). U.S. Cancer Statistics: 2001 Incidence and Mortality. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute: Atlanta.
31. Vlahovic G, Rabbani Z, Herndon II J, Dewhirst M, Vujaskovic Z. (2006). Treatment with imatinib in NSCLC is associated with decrease if phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 95: 1013-1019.
32. Wang J. (2000). Regulation of cell death by the Abl tyrosine kinase. Oncogene 19: 5643-5650.
33. Wen S, Van Etten R. (1997). The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11: 2456-2467.
34. Woodring P, Hunter T, Wang J. (2003). Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Science 116(Part 13): 2613-2626.
35. Zabarovsky E, Lerman M, Minna J. (2002). Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915-6935.
36. Zhang P, Gao W, Turner S, Ducatman B. (2003). Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2: 1.